Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer

a Southwest Oncology Group study

David S Alberts, Nancy Mason, Earl Surwit, Sheldon Weiner, Neel Hammond, Gunther Deppe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The Southwest Oncology Group has carried out a phase I clinical trial of carboplatin plus cyclophosphamide and iproplatin plus cyclophosphamide in 20 patients with stages III and IV ovarian cancer prior to initiating a phase III trial to compare these platinum analogcyclophosphamide combinations with standard cisplatin-cyclophosphamide therapy. Myelosuppression proved the dose-limiting toxicity of both the carboplatin (300 mg/m2) plus cyclophosphamide (600 mg/m2) and iproplatin (180 mg/m2) plus cyclophosphamide (600 mg/m2) regimens. Evaluating up to six courses of therapy (repeated at 4-week intervals), the median nadir WBC and platelet counts associated with carboplatin-cyclophosphamide therapy were 1800 (range, 900-4000) and 69 000 per μl, respectively, and those associated with iproplatin-cyclophosphamide therapy were 1400 (1100-1600) and 140 000 per μl, respectively. Although the starting doses of carboplatin and iproplatin required a median decrease of 25%, the median doses of each administered through six courses of therapy were 300 and 180 mg/m2, respectively. Neither nephrotoxicity nor neuropathy were experienced by the patients, but mild to moderate nausea and vomiting occurred in more than 75% of those treated with either drug combination. Alopecia of mild to severe degree was observed in 40% of patients. Although the results of this phase I trial are still preliminary, we can recommend for future phase III trials 300 mg/m2 carboplatin and 180 mg/m2 iproplatin when combined with 600 mg/m2 cyclophosphamide repeated at 4-week intervals for six treatment courses.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalCancer Treatment Reviews
Volume12
Issue numberSUPPL. A
DOIs
StatePublished - 1985

Fingerprint

Carboplatin
Ovarian Neoplasms
Cyclophosphamide
Therapeutics
Clinical Trials, Phase I
iproplatin
Alopecia
Drug Combinations
Platinum
Platelet Count
Nausea
Cisplatin
Vomiting

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer : a Southwest Oncology Group study. / Alberts, David S; Mason, Nancy; Surwit, Earl; Weiner, Sheldon; Hammond, Neel; Deppe, Gunther.

In: Cancer Treatment Reviews, Vol. 12, No. SUPPL. A, 1985, p. 83-92.

Research output: Contribution to journalArticle

Alberts, David S ; Mason, Nancy ; Surwit, Earl ; Weiner, Sheldon ; Hammond, Neel ; Deppe, Gunther. / Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer : a Southwest Oncology Group study. In: Cancer Treatment Reviews. 1985 ; Vol. 12, No. SUPPL. A. pp. 83-92.
@article{76a6f0218e05448fa3857e67b4b7c318,
title = "Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study",
abstract = "The Southwest Oncology Group has carried out a phase I clinical trial of carboplatin plus cyclophosphamide and iproplatin plus cyclophosphamide in 20 patients with stages III and IV ovarian cancer prior to initiating a phase III trial to compare these platinum analogcyclophosphamide combinations with standard cisplatin-cyclophosphamide therapy. Myelosuppression proved the dose-limiting toxicity of both the carboplatin (300 mg/m2) plus cyclophosphamide (600 mg/m2) and iproplatin (180 mg/m2) plus cyclophosphamide (600 mg/m2) regimens. Evaluating up to six courses of therapy (repeated at 4-week intervals), the median nadir WBC and platelet counts associated with carboplatin-cyclophosphamide therapy were 1800 (range, 900-4000) and 69 000 per μl, respectively, and those associated with iproplatin-cyclophosphamide therapy were 1400 (1100-1600) and 140 000 per μl, respectively. Although the starting doses of carboplatin and iproplatin required a median decrease of 25{\%}, the median doses of each administered through six courses of therapy were 300 and 180 mg/m2, respectively. Neither nephrotoxicity nor neuropathy were experienced by the patients, but mild to moderate nausea and vomiting occurred in more than 75{\%} of those treated with either drug combination. Alopecia of mild to severe degree was observed in 40{\%} of patients. Although the results of this phase I trial are still preliminary, we can recommend for future phase III trials 300 mg/m2 carboplatin and 180 mg/m2 iproplatin when combined with 600 mg/m2 cyclophosphamide repeated at 4-week intervals for six treatment courses.",
author = "Alberts, {David S} and Nancy Mason and Earl Surwit and Sheldon Weiner and Neel Hammond and Gunther Deppe",
year = "1985",
doi = "10.1016/0305-7372(85)90023-4",
language = "English (US)",
volume = "12",
pages = "83--92",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. A",

}

TY - JOUR

T1 - Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer

T2 - a Southwest Oncology Group study

AU - Alberts, David S

AU - Mason, Nancy

AU - Surwit, Earl

AU - Weiner, Sheldon

AU - Hammond, Neel

AU - Deppe, Gunther

PY - 1985

Y1 - 1985

N2 - The Southwest Oncology Group has carried out a phase I clinical trial of carboplatin plus cyclophosphamide and iproplatin plus cyclophosphamide in 20 patients with stages III and IV ovarian cancer prior to initiating a phase III trial to compare these platinum analogcyclophosphamide combinations with standard cisplatin-cyclophosphamide therapy. Myelosuppression proved the dose-limiting toxicity of both the carboplatin (300 mg/m2) plus cyclophosphamide (600 mg/m2) and iproplatin (180 mg/m2) plus cyclophosphamide (600 mg/m2) regimens. Evaluating up to six courses of therapy (repeated at 4-week intervals), the median nadir WBC and platelet counts associated with carboplatin-cyclophosphamide therapy were 1800 (range, 900-4000) and 69 000 per μl, respectively, and those associated with iproplatin-cyclophosphamide therapy were 1400 (1100-1600) and 140 000 per μl, respectively. Although the starting doses of carboplatin and iproplatin required a median decrease of 25%, the median doses of each administered through six courses of therapy were 300 and 180 mg/m2, respectively. Neither nephrotoxicity nor neuropathy were experienced by the patients, but mild to moderate nausea and vomiting occurred in more than 75% of those treated with either drug combination. Alopecia of mild to severe degree was observed in 40% of patients. Although the results of this phase I trial are still preliminary, we can recommend for future phase III trials 300 mg/m2 carboplatin and 180 mg/m2 iproplatin when combined with 600 mg/m2 cyclophosphamide repeated at 4-week intervals for six treatment courses.

AB - The Southwest Oncology Group has carried out a phase I clinical trial of carboplatin plus cyclophosphamide and iproplatin plus cyclophosphamide in 20 patients with stages III and IV ovarian cancer prior to initiating a phase III trial to compare these platinum analogcyclophosphamide combinations with standard cisplatin-cyclophosphamide therapy. Myelosuppression proved the dose-limiting toxicity of both the carboplatin (300 mg/m2) plus cyclophosphamide (600 mg/m2) and iproplatin (180 mg/m2) plus cyclophosphamide (600 mg/m2) regimens. Evaluating up to six courses of therapy (repeated at 4-week intervals), the median nadir WBC and platelet counts associated with carboplatin-cyclophosphamide therapy were 1800 (range, 900-4000) and 69 000 per μl, respectively, and those associated with iproplatin-cyclophosphamide therapy were 1400 (1100-1600) and 140 000 per μl, respectively. Although the starting doses of carboplatin and iproplatin required a median decrease of 25%, the median doses of each administered through six courses of therapy were 300 and 180 mg/m2, respectively. Neither nephrotoxicity nor neuropathy were experienced by the patients, but mild to moderate nausea and vomiting occurred in more than 75% of those treated with either drug combination. Alopecia of mild to severe degree was observed in 40% of patients. Although the results of this phase I trial are still preliminary, we can recommend for future phase III trials 300 mg/m2 carboplatin and 180 mg/m2 iproplatin when combined with 600 mg/m2 cyclophosphamide repeated at 4-week intervals for six treatment courses.

UR - http://www.scopus.com/inward/record.url?scp=0022337584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022337584&partnerID=8YFLogxK

U2 - 10.1016/0305-7372(85)90023-4

DO - 10.1016/0305-7372(85)90023-4

M3 - Article

VL - 12

SP - 83

EP - 92

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. A

ER -